載入...
Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO(®) (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers
BACKGROUND: HCP1004 is a newly developed fixed-dose combination of naproxen (500 mg) and esomeprazole strontium (20 mg) that is used in the treatment of rheumatic diseases and can reduce the risk of nonsteroidal anti-inflammatory drug-associated ulcers. The aim of this study was to evaluate the phar...
Na minha lista:
| 發表在: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Dove Medical Press
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4527374/ https://ncbi.nlm.nih.gov/pubmed/26257511 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S86725 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|